Association of Plasma Neurofilament Light With Neurodegeneration in Patients With Alzheimer Disease.

Mattsson N, Andreasson U, Zetterberg H, Blennow K, Alzheimer’s Disease Neuroimaging Initiative. · 2017

Read Association of Plasma Neurofilament Light With Neurodegeneration in Patients With Alzheimer Disease. by Mattsson N, Andreasson U, Zetterberg H, Blennow K, Alzheimer’s Disease Neuroimaging Initiative. (2017) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5822204.txt.

Introduction

Mattsson and co-authors test a blood marker for Alzheimer disease damage. Neurofilament light, or NFL, leaks from injured nerve fibers. Spinal fluid NFL rises in Alzheimer disease. A blood test would be far easier to use.

An ultrasensitive assay measured plasma NFL in 570 people. Groups held healthy controls, mild impairment, and Alzheimer dementia. Plasma NFL ran high in the disease groups. It also tracked later decline, brain shrinkage, and slowed brain metabolism. The authors see it as a screening and monitoring tool. Readers get evidence for a simple blood signal of nerve damage.

Catalog record

CREATORMattsson N, Andreasson U, Zetterberg H, Blennow K, Alzheimer’s Disease Neuroimaging Initiative.
YEAR2017
COLLECTIONPAPERS
FORMATTXT
FILE SIZE30 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC5822204

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Association of Plasma Neurofilament Light With Neurodegeneration in Patients With Alzheimer Disease By Niklas Mattsson, Ulf Andreasson, Henrik Zetterberg, Kaj Blennow Published in: JAMA Neurology DOI: 10.1001/jamaneurol.2016.6117 ABSTRACT Key Points Question What is the importance of plasma neurofilament light in Alzheimer disease? Findings In this case-control study of 193 cognitively healthy controls, 197 patients with mild cognitive impairment, and 180 patients with Alzheimer disease dementia, plasma neurofilament light was associated with Alzheimer disease and correlated with future progression of cognitive decline, brain atrophy, and brain hypometabolism. Meaning Plasma neurofilament light may be a promising noninvasive biomarker for Alzheimer disease. INTRODUCTION Alzheimer disease (AD) is a neurodegenerative disease that is characterized by brain accumulation of β-amyloid (Aβ) and tau, progressive atrophy, and cognitive decline. Biomarkers that capture biological processes in AD are increasingly used to support the diagnosis of AD in research, drug development, and clinical practice. The most well-established AD biomarkers include structural magnetic resonance imaging (MRI); cerebrospinal fluid (CSF) biomarkers of Aβ, tau, and neuronal injury; and positron emission tomographic imaging of Aβ, tau, and brain metabolism. Use of these biomarkers is hampered by a high degree of invasiveness, high costs, or limited availability. Blood-based biomarkers for AD may allow for efficient monitoring of disease processes in AD and could be used as a screening tool in primary care. One potential blood-based biomarker for AD is the neuronal injury marker neurofilament light (NFL) because patients with AD have increased CSF concentrations of NFL. Results from some studies suggest that patients with AD have increased plasma NFL concentrations. However, those studies were performed using standard immunoassay techniques with suboptimal analytical sensitivity to accurately quantify low abundant brain-specific proteins in blood samples. For this reason, our group has recently transferred the CSF NFL assay to an ultrasensitive single-molecule array (Simoa; Quanterix Corporation) platform, which provides an analytical sensitivity of 0.6 pg/mL compared with 78.0 pg/mL for the corresponding enzyme-linked immunosorbent assay (ELISA). Plasma NFL concentrations can be measured in all samples using the ultrasensitive single-molecule array and correlate closely with the corresponding CSF concentrations. Herein, we test this novel plasma NFL assay in patients with AD for the first time, to our knowledge. We studied cognitively healthy control individuals, patients with mild cognitive impairment (MCI) (MCI group), and patients with AD dementia (AD group) in a large prospective study. We tested the hypotheses that the plasma NFL concentration is increased in AD and that it correlates with impaired cognition, neuroimaging abnormalities, and CSF biomarkers of AD pathologic features. METHODS ADNI Study Design Data were obtained from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database (http://adni.loni.usc.edu). The ADNI was launched in 2003 as a public-private partnership, led by principal investigator Michael W. Weiner, MD (the most recent information on the ADNI is available at http://www.adni-info.org). The ADNI participants have been recruited from more than 50 sites across the United States and Canada. For the present study, we used data accessed from the Laboratory of Neuro Imaging (University of Southern California) ADNI database on October 6, 2016. The study data and samples were collected from September 7, 2005, to February 13, 2012. Regional ethical committees of all participating institutions approved the ADNI. All study participants provided written informed consent. ADNI Participants Our ADNI cohort consisted of all cognitively healthy controls, patients with MCI, and patients with AD dementia with available baseline plasma NFL samples from the ADNI-1. Inclusion and exclusion criteria were described in detail previously. Briefly, all ADNI-1 participants were aged 55 to 90 years, had completed at least 6 years of education, were fluent in Spanish or English, and had no substantial neurological disease other than AD. Controls had Mini-Mental State Examination (MMSE) scores of 24 or higher, where lower scores indicate more impairment and higher scores less impairment (range, 0-30), and a Clinical Dementia Rating (CDR) score of 0, where lower scores indicate less impairment and higher scores more impairment (range, 0-3). Patients with MCI had MMSE scores of 24 or higher, objective memory loss tested by delayed recall of the Wechsler Memory Scale (WMS) logical memory II (>1 SD below the normal mean), a CDR score of 0.5, preserved activities of daily living, and absence of dementia. Patients with AD dementia fulfilled the National Institute of Neurological Communicative Disorders and Stroke–Alzheimer Disease and Related Disorders Association criteria for probable AD, had MMSE scores of 20 to 26, and had CDR scores of 0.5 to 1.0. Plasma NFL Plasma NFL concentrations were measured using an NFL kit (NF-light; UmanDiagnostics), transferred onto the ultrasensitive single-molecule array platform using a home brew kit (Simoa Homebrew Assay Development Kit; Quanterix Corporation), as previously described. In the 14 analytical runs needed to complete the study, the relative error of the back-calculated concentrations was below 20% for all calibrators, run in triplicate, resulting in lower limits of quantifications of 2.2 ng/L and upper limits of quantification of 1620 ng/L. All samples measured within the range spanned by the limits of quantifications, and for the low-concentration quality control sample (14 ng/L), the intra-assay coefficient of variation was 11.0% and the interassay coefficient of variation was 11.1%. For the high-concentration quality control sample (137 ng/L), the corresponding coefficients of variation were 8.8% and 9.6%, respectively. The measurements were performed in September 2016 by a board-certified laboratory technician using a single batch of reagents. CSF Measurements Cerebrospinal fluid was sampled by lumbar puncture from a subset of the participants, with CSF Aβ42, CSF total tau (t-tau), and CSF phosphorylated tau (p-tau) measured using a multiplex platform (xMAP; Luminex Corporation) with a kit (INNO-BIA AlzBio3; Fujirebio Europe). Participants were classified as Aβ positive or Aβ negative using a previously established cutoff (CSF Aβ42 < 192 ng/L). We excluded 8 patients with AD dementia who were Aβ negative and therefore likely to be misdiagnosed. The CSF NFL concentrations were measured using a commercial ELISA (NF-light; UmanDiagnostics) and have been reported previoushy. In total, we included CSF data from 112 controls, 189 patients with MCI, and 90 patients with AD dementia. Cognition Cognition was assessed by MMSE, Alzheimer Disease Assessment Scale–cognitive subscale (ADAS-Cog 11), delayed recall of the WMS logical memory II, Trail-Making test part B (TMT-B), and Wechsler Adult Intelligence Scale–Revised (WAIS-R) digit symbol substitution test. All tests were administered at baseline and at 6, 12, 18, 24, 36, and 48 months, except for delayed recall of the WMS logical memory II, which was not assessed at 18 months. Neuroimaging Structural brain images were acquired using 1.5-T MRI imaging systems with T1-weighted MRI scans using a sagittal volumetric magnetization-prepared rapid acquisition gradient echo sequence (at baseline and at 6, 12, 18, 24, 36, and 48 months). A software program (FreeSurfer; https://surfer.nmr.mgh.harvard.edu/) was used for quantification of cortical thickness and subcortical volumes. We used volumetric data for hippocampal volume and lateral ventricles (averaged between right and left sides). We used the mean cortical thickness for a set of regions defined a priori based on work by Jack et al to represent AD cortex (including entorhinal, inferior temporal, middle temporal, and fusiform cortex). White matter hyperintensities (WMHs) were quantified at baseline and at 6, 12, 18, 24, 36, and 48 months using a fully automated protocol. Positron emission tomography with 18F-fluorodeoxyglucose image data

Read the complete text